Precigen, Inc. (FRA:I5X)

Market Cap	1.32B +214.0%
Revenue (ttm)	5.38M +59.2%
Net Income	-362.97M
EPS	-1.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	130
Open	3.760
Previous Close	3.628
Day's Range	3.754 - 3.760
52-Week Range	1.007 - 4.552
Beta	n/a
RSI	49.01
Earnings Date	Mar 19, 2026

About Precigen

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 143
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I5X

Financial Performance

In 2024, Precigen's revenue was $3.93 million, a decrease of -36.95% compared to the previous year's $6.23 million. Losses were -$126.24 million, 31.6% more than in 2023.

Financial numbers in USD